Senzime Ab · OMXSTO:SEZI
Senzime Ab — Q1 2026 Earnings Presentation
26 slides from Senzime Ab's earnings presentation, Apr 22, 2026
Slide 1: Quarterly Report January–March 2026
Q1 QUARTERLY REPORT JANUARY – MARCH 2026 1 SENZIME QUARTERLY REPORT Q1 2026
Slide 2: Margins strengthened and cash flow improved despite a temporary dip in growth
QUARTERLY REPORT JAN-MAR 2026 Margins strengthened and cash flow Sales of sensors R 12-months (KSEK) 70 000 improved despite a temporary dip in 60 000 50 000 the growth trajectory. Full-year 40 000 30 000 targets remain on track. 20 000 10 000 2026 has started at a strong pace, with improved margins
Slide 3: First quarter 2026 and significant events
QUARTERLY REPORT JAN-MAR 2026 FIRST QUARTER 2026 (1 JANUARY – 31 MARCH) SIGNIFICIANT EVENTS DURING THE FIRST QUARTER • Net sales amounted to SEK 23,233 thousand (23,499), a decrease of 1 % • Senzime secures major agreement with leading Ivy League hospitals in the US. The • Currency-adjusted net sale
Slide 4: KPI's First Quarter 2026
Net Sales Q1 2022-2026 MSEK KPI’s FIRST QUARTER 2026 25 20 Q1 Full Year KSEK 2026 2025 2025 15 15,6 14,8 Net Sales 23,233 23,499 104,022 EBITDA -20,202 -20,838 -99,051 10 Profit (loss) after financial items -23,242 -35,522 -139,039 9 Earnings per share (SEK) -0.14 -0.27 -0.93 5 5 Gross margin excl.
Slide 5: Sales Overview
SALES OVERVIEW Currency Reported adjusted Accumulated number of sold TetraSens SALES (KSEK) Q1 2026 Q1 2025 Growth Growth 1 200 000 US 14,805 15,551 -5% 11% Devices/other 2,537 6,288 -60% -53% Disposables 12,269 9,262 32% 55% Europe 4,857 3,816 27% 32% 1 000 000 Devices/other 1,990 1,916 4% 6% Dispo
Slide 6: This is Senzime.
This is Senzime. Senzime is a global medical technology company that develops algorithm-based patient monitoring systems with the goal of eliminating anesthesia related complications in over 100 million patients every year. Our systems enable precision-based monitoring of patients during and after s
Slide 7: A comment from the CEO
In Japan, the Next-gen TetraGraph is now being rolled out to market following the A comment from the CEO December 2025 PMDA market approval. First hospital contracts have been secured. In South Korea, the regulatory approval process for the Next-gen TetraGraph continues. Margins strengthened and cas
Slide 8: CEO comment continued: TetraCom and installed base
We continue to advance new innovations with the launch of the TetraCom, the first AI- compatible integration platform specifically developed for neuromuscular anesthesia data in an operating room environment. With TetraCom, we can generate additional growth and value from the data generated by the T
Slide 9: Comments to the Q1 report
Comments to the Q1 report Revenue and profit in the first quarter of 2026 The Group’s net sales for the first quarter of 2026 amounted to SEK 23,233 thousand The underlying gross margin, adjusted for currency and tariff effects, amounted to (23,499), a decrease of 1 percent compared with the corresp
Slide 10: Parent company and subsidiaries, financial position, sustainability
Cash flow from investing activities amounted to SEK -2,798 thousand (-5,034). Parent company and subsidiaries Investments during the period are largely related to capitalization of development The majority of the Group's operations are conducted in the Parent Company. For projects. During the first
Slide 11: Other significant events in the quarter
Other significant events in the quarter Geopolitical situation Senzime secured major agreement with leading Ivy League hospitals in the US. The Senzime has no operations in Russia, Ukraine, Israel, Iran, Lebanon or Palestine. The agreement included an initial installation of 60 next-generation Tetra
Slide 12: Condensed Consolidated Statement of Comprehensive Income
Condensed Consolidated Statement of Comprehensive Income Q1 Full-year Amounts in SEK thousands Note 2026 2025 2025 Net sales 2 23,233 23,499 104,022 Cost of goods sold 3 -13,557 -13,099 -69,330 Gross profit (loss) 9,676 10,400 34,692 Development expenditure 4 -5,667 -4,400 -22,852 Selling expenses 4
Slide 13: Condensed Consolidated Statement of Comprehensive Income
Condensed Consolidated Statement of Comprehensive Income Q1 Full-year Amounts in SEK thousands Note 2026 2025 2025 Profit (-loss) for the period -22,512 -34,662 -137,419 Other comprehensive income Items reclassifiable to profit or loss Translation differences 1,454 -5,502 -9,477 Total comprehensive
Slide 14: Condensed Consolidated Balance Sheet Assets
Condensed Consolidated Balance Sheet Assets March 31 December 31 Amounts in SEK thousands 2026 2025 2025 ASSETS Non-current assets Intangible assets 220,801 235,886 219,000 Property plant and equipment 4,916 3,682 4,462 Rights of use 14,082 17,675 13,850 Other financial assets 4,497 5,112 4,614 Tota
Slide 15: Condensed Consolidated Balance Sheet Equity and Liabilities
Condensed Consolidated Balance Sheet Equity and Liabilities March 31 December 31 Amounts in SEK thousands 2026 2025 2025 EQUITY AND LIABILITIES Equity 283,500 305,888 304,461 LIABILITIES Non-current liabilities Provisions 4,497 4,643 4,614 Interest-bearing liabilities 7,500 - - Lease liability 12,26
Slide 16: Condensed Consolidated Statement of Change in Equity
Condensed Consolidated Statement of Change in Equity Attributable to parent company´s shareholders Amounts in SEK thousands Share capital Other contributed capital Reserves Retained earnings incl.profit (loss) for the year Total equity Adjusted opening balance as of 1 January 2025 16,647 959,021 9,1
Slide 17: Condensed Consolidated Statement of Cash Flow
Condensed Consolidated Statement of Cash Flow Q1 Full-year Amounts in SEK thousands 2026 2025 2025 Cash flow from operating activities Earnings before interest and taxes -25,886 -26,897 -122,575 Adjustment for non-cash items Depreciation and amortization 5,684 6,058 23,524 Other non-cash items -3,48
Slide 18: Parent company Income Statement
Parent company Income Statement Q1 Full-year Amounts in SEK thousands 2026 2025 2025 Net sales 14,622 27,377 82,827 Cost of goods sold -10,100 -10,316 -59,577 Gross profit (loss) 4,522 17,061 23,250 Development expenditure -4,478 -3,351 -17,898 Selling expenses -3,643 -3,402 -86,604 Administrative e
Slide 19: Parent Company Balance Sheet Assets
Parent Company Balance Sheet Assets March 31 December 31 Amounts in SEK thousands 2026 2025 2025 ASSETS Non-current assets Intangible fixed assets 61,496 53,708 60,743 Property plant and equipment 3,793 3,328 3,943 Financial assets 114,262 114,373 108,760 Total non-current assets 179,551 171,409 173
Slide 20: Parent Company Balance Sheet Equity and Liabilities
Parent Company Balance Sheet Equity and Liabilities March 31 December 31 Amounts in SEK thousands 2026 2025 2025 EQUITY AND LIABILITIES Equity Restricted equtiy 84,782 73,800 83,981 Non-restricted equity 123,506 162,384 132,558 Total equity 208,288 236,184 216,539 LIABILITIES Interest-bearing liabil
Slide 21: Notes on the consolidated accounts
Notes on the consolidated accounts Note 1. Accounting policies Note 3. Costs of goods sold Q1 Full-year Amounts in SEK thousands 2026 2025 2025 This interim report and summary for the first quarter ended March 31, 2026 has been Cost of materials 6,565 6,843 41,850 prepared in accordance with the Int
Slide 22: Earnings per share
Q1 Full-year SEK 2026 2025 2025 Basic earnings per share -0.14 -0.27 -0.93 Diluted earnings per share -0.14 -0.27 -0.93 Performance measure used in the calculation of earnings per share Results attributable to the parent company's shareholders are used Profit (-loss) for the period Profit (-loss) fo
Slide 23: Note 7. Share capital development
Note 7. Share capital development Date Event Number of shares Share capital (SEK) Quotient value (SEK) Januari 1,2024 Opening balance 119,705,523 14,963,190 0.125 October 18, 2024 Directed share issue part 1 12,769,000 1,596,125 0.125 December 19, 2024 Directed share issue part 2 700,000 87,500 0.12
Slide 24: Note 8. Alternative performance measures
Note 8. Alternative performance measures Senzime has defined alternative key figures as below. Calculations are published on the company's website www.senzime.com. Performance measure Definition Motive for use Gross margin excl. Gross profit (loss) excl. amortization of intangible assets The group u
Slide 25: Note 9. Alternative performance measures; Note 10. Employee stock option programs
Note 9. Alternative performance measures Note 10. Employee stock option programs Q1 Full-year 2026 2025 2025 A Net sales, TSEK 23,233 23,499 104,022 B Gross profit excl. amortization, TSEK 14,651 15,485 54,712 At the time of publication of this interim report, there are four employee stock option B/
Slide 26: Safeguarding every patient's journey, from anesthesia to recovery
Safeguarding every patient's journey, from anesthesia to recovery. Financial calendar Contacts Annual Report 2025 Apr 24, 2026 Philip Siberg, CEO Slavoljub Grujicic, CFO AGM 2026 May 19, 2026 Tel. +46 (0) 707 90 67 34 Tel. +46 (0) 763 06 60 11 Interim report Q2 2026 Jul 16, 2026 philip.siberg@senzim